Pune : Deccan Express | Russian vaccine Sputnik again Coronavirus will be produced in Serum Institute of India’s manufacturing facility in Pune from September this year.
SII is the world’s largest company in terms of COVID vaccines production with over 500 million doses manufactured. Through several strategic associations, SII has been front running India’s fight against the pandemic. In addition to developing its own vaccine, it is currently manufacturing Covishield (developed by AstraZeneca-Oxford), Covovax (by Novavax) and conducting trials of Codagenix in UK.
The first batch of Sputnik vaccine is expected to be produced at SII’s facilities in September. The parties intend to produce over 300 million doses of the vaccine in India per year.
As part of the technical transfer process, SII has already received cell and vector samples from the Gamaleya Center. With their import approved by the Drug Controller General of India (DCGI), the cultivation process has begun.
Panacea Biotec, Stelis Biopharma, Virchow Biotech and Morepen) for production of the Russian vaccine.
To date, Russian Sputnik V vaccine has been registered in 67 countries globally with a total population of over 3.5 bn people.
The data obtained by regulators of a number of countries during the vaccination of the population,
including in Argentina, Serbia, Bahrain, Hungary, Mexico, San Marino, UAE and others,
demonstrates that Sputnik V is one of the safest and most effective vaccines against coronavirus.
Kirill Dmitriev, CEO of the Russian Direct Investment Fund, “RDIF is delighted to cooperate with Serum Institute of India, the world’s largest vaccine manufacturer.
This strategic partnership is a major step to substantially increase our production capabilities demonstrating a perfect example of joining forces and expertise to save lives both in India and around the world.
With technology transfer underway we expect the first batches of the vaccine to be produced jointly with SII in coming months.”
Adar Poonawalla, CEO of Serum Institute of India said
“I am delighted to partner with RDIF to manufacture the Sputnik vaccine.
We hope to make millions of doses in the coming months with trial batches starting in the month of September. With high efficacy and a good safety profile,
it is critical that the Sputnik vaccine is accessible in full measure for people across India and the world.
Given the uncertainty of the virus, it is important for international institutes,
and governments to collaborate and further bolster up our fight against the pandemic.”